Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients

OncotypeDX and MammaPrint assays have not been validated to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in early-stage breast cancer patients. We analyzed the 2010–2019 National Cancer Database and found that high OncotypeDX recurrence scores or high MammaPrint scor...

Descripción completa

Detalles Bibliográficos
Autores principales: Freeman, Jincong Q., Shubeck, Sarah, Howard, Frederick M., Chen, Nan, Nanda, Rita, Huo, Dezheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164191/
https://www.ncbi.nlm.nih.gov/pubmed/37149628
http://dx.doi.org/10.1038/s41523-023-00536-z
Descripción
Sumario:OncotypeDX and MammaPrint assays have not been validated to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in early-stage breast cancer patients. We analyzed the 2010–2019 National Cancer Database and found that high OncotypeDX recurrence scores or high MammaPrint scores were associated with greater odds of pCR. Our findings suggest that OncotypeDX and MammaPrint testing predict pCR after NACT and could facilitate clinical decision-making between clinicians and patients.

Ejemplares similares